# FUTURE-SUPER

Source: https://onco.cc/trials/future-super/  
OnCo record `future-super` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

FUTURE-SUPER tested a defined subtype-linked treatment strategy in advanced TNBC. The pooled phase 2 PFS comparison was positive; the current registry does not establish availability.

## Summary

Single-centre, open-label phase 2 study at Fudan University Shanghai Cancer Center. Participants were women aged 18-70, ECOG 0-1, with untreated metastatic or recurrent TNBC. Five cohorts combined a Fudan subtype classification with genomic biomarkers. Within that strategy, 139 participants were randomised to matched additions to nab-paclitaxel (69) or nab-paclitaxel alone (70). This is a different classifier from Lehmann TNBCtype-4.

The primary comparison was investigator-assessed progression-free survival in the pooled intention-to-treat groups. At the 31 May 2023 cutoff, median follow-up was 22.5 months (interquartile range 15.2-29.0). It tested a package of classification, matching rules and regimens; it did not separately establish each component's effect.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-11-09
- Also known as: FUTURE SUPER; NCT04395989
- Tags: education-audit; subtyping-strategy
- Registry id: NCT04395989
- Phase: 2
- Setting: Single-centre first-line untreated metastatic/recurrent TNBC; Fudan subtype/genomic-marker cohorts, matched combinations plus nab-paclitaxel versus nab-paclitaxel alone
- Sponsor: Fudan University
- Enrolled: 139
- Result: At the 31 May 2023 analysis, median PFS was 11.3 versus 5.8 months, hazard ratio 0.44 (95 percent confidence interval 0.30-0.65). Treatment-related serious events occurred in 7/69 versus 0/70.
- Outcomes: Investigator-assessed progression-free survival, pooled intention-to-treat comparison: Subtype/genomic-marker strategy plus nab-paclitaxel 11.3 months vs Nab-paclitaxel alone 5.8 months, HR 0.44
- Replication: This single-centre phase 2 strategy result does not isolate a classifier or individual matched component; independent larger comparative validation and setting-specific comparators remain important.

## Notes

- The four Fudan subtype labels generated five treatment cohorts after genomic splitting. Additions included pyrotinib for LAR with activating HER2 mutation; everolimus in specified PI3K/AKT-altered LAR/MES groups; camrelizumab plus famitinib in IM; and bevacizumab in BLIS/MES without those alterations. This does not equate those groups with TNBCtype-4 or pathology receptor labels.
- The positive outcome label refers to the published pooled primary comparison. Registry recruitment status captured on 9 November 2026 is UNKNOWN, last known ACTIVE_NOT_RECRUITING; last posted update 22 December 2023. It is not an available-slot claim. Registry actual enrollment is 139 and no results module is posted.
- The registry uses enrollment for its PFS clock and first dose for its secondary OS clock. Do not silently make those endpoints share a start or turn the PFS result into a demonstrated OS benefit.

## Sources

- ClinicalTrials.gov NCT04395989: https://clinicaltrials.gov/study/NCT04395989
- Fan et al., Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial (Lancet Oncol 2024): https://pubmed.ncbi.nlm.nih.gov/38211606/

## Connected records

- key papers: [FUTURE-SUPER: first-line subtyping-based treatment in advanced TNBC](https://onco.cc/key-papers/paper-future-super-lancet-oncology-2024/)
- cancers: [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Camrelizumab](https://onco.cc/drugs/camrelizumab/), [Everolimus](https://onco.cc/drugs/everolimus/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/), [Pyrotinib](https://onco.cc/drugs/pyrotinib/)
- terms: [TNBC molecular subtyping](https://onco.cc/terms/tnbc-molecular-subtyping/)
- people: [Yi-Zhou Jiang](https://onco.cc/people/jiang-yi-zhou/), [Zhi-Ming Shao](https://onco.cc/people/shao-zhi-ming/)

---
JSON: https://onco.cc/api/v1/entities/future-super.json